Best Practices For Evaluating Immunologically Active Compounds

An Interview With Matthijs Moerland, Research Director R&D lab and Immunology

Because the immune system is extraordinarily complex and tightly regulated, every new immune-based therapy must undergo rigorous and comprehensive evaluation before it can advance in development. Early-phase clinical testing of immunologically active compounds demands not only cutting-edge scientific understanding but also deep clinical expertise to safeguard participant well-being while maximizing both clinical insight and economic value.

At CHDR, we are dedicated to addressing the scientific and operational challenges that accompany the early clinical development of novel immunotherapies. Over the past several years, CHDR has developed and validated a range of innovative methodologies for assessing immunologically active drugs. Leveraging in vivo, in vitro, and ex vivo systems, our researchers can systematically characterize immune responses, evaluate compound safety and efficacy, and generate high-quality translational data during the earliest phases of development.

To explore these advancements further, we spoke with Dr. Matthijs Moerland, Research Director of R&D Lab and Immunology at CHDR, who shared his insights on the evolving landscape of immune-based drug development and the best practices CROs should adopt to overcome its unique challenges.